Collegium Pharmaceutical, Inc. (COLL) Income Statement
COLL 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCOLL revenue and net income
Where COLL's revenue goes
2025Each bar shows an amount and its share of revenue. COLL kept 8.1% of revenue as net income.
COLL profit margins
COLL growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +23.6% | +18.9% | +20.3% | — |
| Gross profit | +22.8% | +30.3% | +20.8% | — |
| Operating income | +10.1% | +77.7% | +27.2% | — |
| Net income | −9.1% | — | +18.6% | — |
| EPS (diluted) | +9.5% | +32.9% | +26.4% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
COLL quarterly EPS vs estimates
Collegium Pharmaceutical beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 5, 2026 (estimate $1.53).
COLL income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M | $310.0M | $296.7M | $280.4M | $28.5M | $1.7M |
| Cost of revenue | $317.3M | $254.1M | $240.6M | $254.4M | $126.3M | $130.2M | $193.7M | $165.7M | $2.6M | $213,000 |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M | $179.8M | $103.0M | $114.7M | $25.9M | $1.5M |
| Research & development | — | $0 | $0 | $4.0M | $9.5M | $9.8M | $10.3M | $8.7M | $8.6M | $14.9M |
| Sales, general & admin | $284.8M | $183.0M | $159.2M | $172.2M | $119.0M | $113.8M | $116.4M | $126.8M | $92.8M | $80.6M |
| Total operating expenses | $276.2M | $207.4M | $159.2M | $176.2M | $133.0M | $123.6M | $126.8M | $135.4M | $101.3M | $95.6M |
| Operating income | $187.1M | $169.9M | $167.0M | $33.3M | $17.6M | $56.2M | −$23.7M | −$20.7M | −$75.4M | −$94.1M |
| Interest income | $11.3M | $14.0M | $15.6M | $1.0M | $12,000 | $232,000 | $1.9M | $1.7M | $582,000 | $94,000 |
| Interest expense | $82.3M | $74.0M | $83.3M | $63.2M | $21.0M | $28.9M | $909,000 | $20.1M | $582,000 | $94,000 |
| Income before taxes | $92.6M | $98.6M | $75.7M | −$28.8M | −$3.4M | $27.6M | −$22.7M | −$39.1M | −$74.9M | −$94.2M |
| Income taxes | $29.7M | $29.4M | $27.6M | −$3.8M | −$74.9M | $830,000 | −$14.6M | −$110.9M | −$1.2M | $94,000 |
| Net income | $62.9M | $69.2M | $48.2M | −$25.0M | $71.5M | $26.8M | −$22.7M | −$39.1M | −$74.9M | −$94.2M |
| EBITDA | $401.0M | $341.7M | $308.3M | $173.3M | $86.6M | $118.0M | −$6.3M | $91.9M | −$74.3M | −$93.4M |
| EPS (diluted) | $7.06 | $6.45 | $5.50 | $3.01 | $2.04 | $2.19 | $0.25 | −$0.70 | −$2.50 | −$3.88 |
| Gross margin | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% | 58.0% | 34.7% | 40.9% | 90.9% | 87.6% |
| Operating margin | 24.0% | 26.9% | 29.5% | 7.2% | 6.4% | 18.1% | −8.0% | −7.4% | −264.9% | −5,498.7% |
| Net margin | 8.1% | 11.0% | 8.5% | −5.4% | 25.8% | 8.6% | −7.7% | −14.0% | −262.9% | −5,504.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $199.9M | $193.5M | $205.4M | $209.4M | $188.0M | $177.8M | $181.9M | $159.3M | $145.3M | $144.9M | $149.7M | $136.7M |
| Cost of revenue | $89.6M | $76.3M | $77.1M | $80.2M | $79.6M | $80.4M | $83.7M | $62.5M | $54.5M | $53.5M | $55.1M | $56.4M |
| Gross profit | $110.3M | $117.2M | $128.4M | $129.2M | $108.4M | $97.3M | $98.3M | $96.8M | $90.8M | $91.5M | $94.6M | $80.3M |
| Research & development | — | — | — | — | — | — | — | — | — | — | $0 | $0 |
| Sales, general & admin | $106.6M | $86.3M | $67.6M | $67.1M | $73.6M | $76.4M | $58.6M | $62.0M | $43.3M | $42.0M | $32.9M | $35.3M |
| Total operating expenses | $106.6M | $85.3M | $69.2M | $65.6M | $73.3M | $75.6M | $60.2M | $62.0M | $43.3M | $42.0M | $32.9M | $35.3M |
| Operating income | $3.7M | $32.0M | $59.2M | $63.6M | $35.1M | $21.7M | $38.1M | $34.8M | $47.5M | $49.5M | $61.7M | $45.0M |
| Interest income | $2.3M | $3.7M | $3.6M | $3.1M | $2.4M | $2.2M | $1.8M | $3.3M | $4.4M | $4.5M | $4.3M | $4.5M |
| Interest expense | $19.5M | $15.9M | $104.8M | $21.8M | $20.5M | $20.8M | $22.7M | $18.4M | $15.6M | $17.3M | $19.3M | $20.8M |
| Income before taxes | −$13.5M | $18.7M | $29.0M | $43.4M | $17.0M | $3.1M | $17.3M | $15.6M | $29.1M | $36.6M | $46.7M | $28.8M |
| Income taxes | $1.5M | $4.2M | $12.1M | $11.9M | $5.0M | $705,000 | $4.7M | $6.2M | $9.5M | $8.9M | $14.8M | $8.1M |
| Net income | −$15.1M | $14.5M | $17.0M | $31.5M | $12.0M | $2.4M | $12.5M | $9.3M | $19.6M | $27.7M | $31.9M | $20.6M |
| EBITDA | $71.4M | $90.1M | $190.2M | $121.7M | $94.1M | $80.5M | $96.4M | $75.7M | $80.2M | $89.4M | $101.5M | $86.7M |
| EPS (diluted) | $1.57 | $1.76 | $1.85 | $2.25 | $1.47 | $1.49 | $1.77 | $1.61 | $1.62 | $1.45 | $1.58 | $1.34 |
| Gross margin | 55.2% | 60.6% | 62.5% | 61.7% | 57.7% | 54.8% | 54.0% | 60.8% | 62.5% | 63.1% | 63.2% | 58.7% |
| Operating margin | 1.9% | 16.5% | 28.8% | 30.4% | 18.7% | 12.2% | 20.9% | 21.9% | 32.7% | 34.1% | 41.2% | 32.9% |
| Net margin | −7.5% | 7.5% | 8.3% | 15.0% | 6.4% | 1.4% | 6.9% | 5.9% | 13.5% | 19.1% | 21.3% | 15.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in COLL's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
COLL financial results
In fiscal year 2025 (ended December 31, 2025), Collegium Pharmaceutical reported revenue of $780.6 million, up 23.6% from the year before. It had net income of $62.9 million (down 9.1%), a net profit margin of 8.1%. Diluted earnings per share came to $7.06. Over five years revenue grew at an average rate of 20.3% a year.
See the COLL stock overview for the latest quote and news, or the COLL chart for price history and technical indicators.
COLL income statement FAQ
What is Collegium Pharmaceutical's annual revenue?
Collegium Pharmaceutical reported total revenue of $780.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 23.6% from $631.4 million the previous year.
Is Collegium Pharmaceutical profitable?
Yes. Collegium Pharmaceutical reported net income of $62.9 million in fiscal 2025, a net profit margin of 8.1%; its operating margin was 24.0%.
What is Collegium Pharmaceutical's gross margin?
Collegium Pharmaceutical's gross margin was 59.3% in fiscal 2025: for every $100 of revenue, Collegium Pharmaceutical kept $59 after the direct cost of its products and services.
How fast is Collegium Pharmaceutical growing?
Revenue grew 20.3% a year on average over the last five fiscal years, from $310.0 million to $780.6 million.
What are Collegium Pharmaceutical's earnings per share?
Collegium Pharmaceutical earned $7.06 per diluted share in fiscal 2025, compared with $6.45 a year earlier.
When will Collegium Pharmaceutical report its next earnings?
Collegium Pharmaceutical is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Collegium Pharmaceutical's fiscal year end?
Collegium Pharmaceutical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.